Public Employees Retirement System of Ohio boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 67,131 shares of the life sciences company’s stock after buying an additional 59 shares during the period. Public Employees Retirement System of Ohio’s holdings in Illumina were worth $11,455,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of ILMN. Dimensional Fund Advisors LP increased its stake in shares of Illumina by 0.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 255,908 shares of the life sciences company’s stock valued at $32,768,000 after buying an additional 2,258 shares during the last quarter. Federated Investors Inc. PA increased its stake in shares of Illumina by 14.1% in the fourth quarter. Federated Investors Inc. PA now owns 4,106 shares of the life sciences company’s stock valued at $525,000 after buying an additional 508 shares during the last quarter. Janus Capital Management LLC increased its stake in shares of Illumina by 678.1% in the fourth quarter. Janus Capital Management LLC now owns 240,583 shares of the life sciences company’s stock valued at $30,804,000 after buying an additional 209,665 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Illumina by 12.4% in the fourth quarter. AQR Capital Management LLC now owns 68,757 shares of the life sciences company’s stock valued at $8,804,000 after buying an additional 7,592 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Illumina during the fourth quarter valued at $140,899,000. 93.77% of the stock is currently owned by institutional investors and hedge funds.

Shares of Illumina, Inc. (NASDAQ ILMN) traded up 1.0661% during trading on Wednesday, reaching $178.2401. 198,477 shares of the company traded hands. The firm has a market capitalization of $26.02 billion, a PE ratio of 36.0737 and a beta of 0.76. Illumina, Inc. has a 12 month low of $119.37 and a 12 month high of $189.48. The firm has a 50-day moving average price of $178.46 and a 200-day moving average price of $163.47.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.64. Illumina had a net margin of 30.75% and a return on equity of 21.21%. The firm had revenue of $598 million for the quarter, compared to the consensus estimate of $590.51 million. During the same quarter in the previous year, the company earned $0.71 earnings per share. The business’s revenue was up 4.5% compared to the same quarter last year. Equities research analysts anticipate that Illumina, Inc. will post $3.63 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/illumina-inc-ilmn-position-boosted-by-public-employees-retirement-system-of-ohio/1399933.html.

Several analysts have recently weighed in on ILMN shares. Vetr raised shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $184.98 target price on the stock in a report on Tuesday, March 14th. BTIG Research reaffirmed a “hold” rating on shares of Illumina in a report on Sunday, March 19th. Leerink Swann raised shares of Illumina from a “market perform” rating to an “outperform” rating and set a $195.00 price objective on the stock in a report on Monday, March 20th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $191.00 price objective on the stock in a report on Tuesday, April 4th. Finally, TheStreet raised shares of Illumina from a “c+” rating to a “b” rating in a report on Thursday, April 6th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $165.02.

In other news, insider Michel Bouchard sold 5,740 shares of the business’s stock in a transaction on Tuesday, May 9th. The shares were sold at an average price of $184.68, for a total value of $1,060,063.20. Following the sale, the insider now owns 22,255 shares in the company, valued at approximately $4,110,053.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Charles Dadswell sold 1,609 shares of the business’s stock in a transaction on Wednesday, May 3rd. The shares were sold at an average price of $187.07, for a total transaction of $300,995.63. Following the completion of the sale, the senior vice president now owns 10,936 shares in the company, valued at approximately $2,045,797.52. The disclosure for this sale can be found here. Insiders have sold 95,031 shares of company stock worth $17,086,968 in the last quarter. Corporate insiders own 1.60% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.